Posted by Michael Wonder on 13 May 2021
Palisade Bio receives FDA fast track designation for LB1148 for reduction of adhesions following abdominal and pelvic surgery
13 May 2021 - LB1148 was previously granted fast track designation from the U.S. FDA for the treatment of post-operative GI dysfunction associated with paediatric cardiovascular surgery.
Palisade Bio today announced the U.S. FDA has granted fast track designation to the investigational drug LB1148, which has the potential to be the first oral treatment to reduce adhesions following abdominal or pelvic surgery.
